⌕
EyePoint · EYPT · Nasdaq
Tenet 44 · Weak
Compare
$0.31+0.52%At closeTenet 44 · Weak
$0.310.00 (+0.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

EyePoint (EYPT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 12, 2026 · 11:48 ET
EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript

EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript…

● PRNewsWireNov 12, 2026 · 11:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton a…

● Zacks Investment ResearchNov 12, 2026 · 09:35 ET
EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.…

● GlobeNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

– Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity bl…

● GlobeNewsWireNov 6, 2026 · 07:00 ETCOMPANY'S OWN WORDS
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings

WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal disea…

● PRNewsWireNov 5, 2026 · 19:42 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).  Such investors are advised to contact Danielle Peyton a…

● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal disea…

● PRNewsWireOct 29, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton a…

● Zacks Investment ResearchOct 28, 2026 · 11:06 ET
EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● GlobeNewsWireOct 26, 2026 · 11:46 ETCOMPANY'S OWN WORDS
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law violations on behalf of E…

● GlobeNewsWireOct 22, 2026 · 10:15 ET
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)

DURAVYU's Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have legal rights arising …

● Defense WorldOct 21, 2026 · 04:09 ET
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss

What happened EyePoint, Inc. (NASDAQ: EYPT) said on October 19, 2026 that it is shifting its focus to DURAVYU for diabetic macular edema after LUCIA missed its primary endpoint. The board approved a plan to cut the workf…

● GuruFocusOct 20, 2026 · 11:00 ET
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026…

● PRNewsWireOct 19, 2026 · 17:58 ET
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential secu…

● BenzingaOct 19, 2026 · 13:16 ET
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus

EyePoint Inc. (NASDAQ:EYPT) is slashing its workforce by 53% and halting wet age-related macular degeneration clinical trials early following disappointing Phase 3 results.…

● Seeking AlphaOct 19, 2026 · 13:04 ET
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript

EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript…

● GlobeNewsWireOct 19, 2026 · 07:15 ET
EyePoint Announces Strategic Prioritization

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal disea…

● GlobeNewsWireOct 19, 2026 · 07:00 ET
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were m…

● Defense WorldOct 17, 2026 · 03:29 ET
Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ: SXTP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two b…

● Zacks Investment ResearchOct 15, 2026 · 12:05 ET
Here's Why You Should Add EYPT Stock to Your Portfolio Now

EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.…

● GlobeNewsWireOct 6, 2026 · 17:36 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT).  Such investors are advised to contact Danielle Pey…

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.